Clinical Scorecard: Pediatric Clinical Progression Scale: An Emerging Tool for Assessing Severity and Advancement of Respiratory Syncytial Virus in Children

At a Glance

Key Highlights

• RSV causes significant morbidity with 33 million acute lower respiratory infections and 3.6 million hospitalizations annually worldwide.
• CPS-Ped score ranges from 0 (discharged at baseline) to 8 (death) and assesses clinical improvement over hospitalization days.
• CPS-Ped requires fewer participants in clinical trials to detect treatment effects compared to traditional outcomes like length of stay.

Guideline-Based Recommendations

Diagnosis

• Use CPS-Ped score to assess severity and clinical progression in infants hospitalized with RSV.
• Apply PALICC-2 guidelines for stratifying severe respiratory outcomes within the CPS-Ped framework.

Management

• Consider nirsevimab monoclonal antibody for RSV prevention in infants under 8 months during RSV season and certain high-risk infants in their second season.
• Maternal vaccination with Abrysvo between 32 and 36 weeks gestation is recommended to protect infants during their first RSV season.
• Recognize the need for RSV antivirals for infected children, especially those not eligible for prophylaxis.

Monitoring & Follow-up

• Calculate CPS-Ped scores at admission and serially on days 2–7, 10, and 14 to monitor clinical improvement.
• Define clinical improvement as CPS-Ped score ≤2 or a decrease of ≥3 points from admission score.

Risks

• Infants <3 months, premature infants (especially <29 weeks gestation), those with underlying respiratory conditions, and those requiring invasive mechanical ventilation within 24 hours have higher risk of poor clinical improvement.

Patient & Prescribing Data

Infants under 8 months of age during their first RSV season and certain high-risk infants in their second season

Nirsevimab and maternal Abrysvo vaccination are safe and efficacious but limited by cost and accessibility, leaving many infants unprotected.

Clinical Best Practices

• Utilize CPS-Ped as a standardized, clinically meaningful outcome metric in pediatric RSV clinical trials to improve detection of treatment effects.
• Incorporate multiple levels of respiratory support in severity scoring to reflect current clinical practices, including high-flow nasal cannula use.
• Leverage electronic health record integration for automated CPS-Ped scoring to facilitate large-scale studies.
• Be aware of practice variability in respiratory support modalities when interpreting CPS-Ped scores.

References

• Nirsevimab recommendation and RSV burden
• Abrysvo maternal vaccination
• Leland et al study on CPS-Ped score
• PALICC-2 guidelines for pediatric ARDS
• WHO Clinical Progression Scale for adults